Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 3/20 | 0.56 |
| ▸ | ESR1 | P03372 | 7/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.51 |
| ▸ | P4HB | P07237 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA3 | P07451 | 3/20 | 0.44 |
| ▸ | CA4 | P22748 | 3/20 | 0.44 |
| ▸ | CA6 | P23280 | 3/20 | 0.44 |
| ▸ | CA5A | P35218 | 3/20 | 0.44 |
| ▸ | CA7 | P43166 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.44 |
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3468472 | 1.00 | SNCA (0.56) | SNCAESR1ESR2P4HBKDM4E | |
| SCHEMBL3468122 | 1.00 | SNCA (0.56) | SNCAESR1ESR2P4HBKDM4E | |
| SCHEMBL3468123 | 1.00 | SNCA (0.56) | SNCAESR1ESR2P4HBKDM4E | |
| SCHEMBL3468077 | 0.86 | ESR1 (0.52) | SNCAESR1ESR2KDM4ECA12 | |
| SCHEMBL3468075 | 0.86 | ESR1 (0.52) | SNCAESR1ESR2KDM4ECA12 | |
| SCHEMBL3468205 | 0.85 | ESR1 (0.51) | SNCAESR1ESR2KDM4ECA12 | |
| SCHEMBL3468165 | 0.85 | ESR1 (0.51) | SNCAESR1ESR2KDM4ECA12 | |
| SCHEMBL3468168 | 0.85 | ESR1 (0.51) | SNCAESR1ESR2KDM4ECA12 | |
| SCHEMBL3468202 | 0.85 | ESR1 (0.51) | SNCAESR1ESR2KDM4ECA12 | |
| SCHEMBL4254773 | 0.83 | SNCA (0.48) | SNCAESR1ESR2P4HBTTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213348-A1 | Chemical Compounds | BRITTON JONATHAN E | 2007-09-13 | — | — | US | claimed |
| JP-2007500705-A | — | — | 2007-01-18 | — | — | JP | claimed |
| EP-1667955-A2 | CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF THE ESTROGEN RECEPTOR | SmithKline Beecham Corporation (US) | 2006-06-14 | — | — | EP | claimed |
| WO-2005012220-A9 | CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF ESTROGEN RECEPTOR | SMITHKLINE BEECHAM CORP (US) | 2005-05-19 | — | — | WO | claimed |
| WO-2005012220-A2 | CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF ESTROGEN RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-10 | — | — | WO | claimed |
| US-7799828-B2 | Cycloalkylidene compounds as modulators of estrogen receptor | GLAXOSMITHKLINE LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090253659-A1 | Cycloalkylidene Compounds As Modulators of Estrogen Receptor | GLAXOSMITHKLINE LLC | 2009-10-08 | — | — | US | disclosed |
| US-7569601-B2 | Cycloalkylidene compounds as modulators of estrogen receptor | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-04 | — | — | US | disclosed |
| US-7560589-B2 | Cycloalkylidene compounds as modulators of estrogen receptor | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| US-20070213348-A1 | Chemical Compounds | BRITTON JONATHAN E | 2007-09-13 | — | — | US | disclosed |
| US-20070155839-A1 | Cycloalkylidene compounds as modulators of estrogen receptor | SMITHKLINE BEECHAM CORPORATION | 2007-07-05 | — | — | US | disclosed |
| EP-1667955-A2 | CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF THE ESTROGEN RECEPTOR | SmithKline Beecham Corporation (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005012220-A9 | CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF ESTROGEN RECEPTOR | SMITHKLINE BEECHAM CORP (US) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005012220-A2 | CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF ESTROGEN RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155839-A1 | Cycloalkylidene compounds as modulators of estrogen receptor | ESR2, GPER1, ESRRG | SNCA 4741/4885ESR1 4/4885ESR2 1/4885 |
| US-20090253659-A1 | Cycloalkylidene Compounds As Modulators of Estrogen Receptor | ESR2, GPER1, ESRRG | SNCA 4741/4885ESR1 4/4885ESR2 1/4885 |
| US-20070213348-A1 | Chemical Compounds | GPER1, ESR2, ESR1 | SNCA 4701/4885ESR1 3/4885ESR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.